Five things for pharma marketers to know: Wednesday, April 11, 2018
Alexion Pharmaceuticals has struck a deal to buy Sweden-based Wilson Therapeutics for $855 million in the latest in a string of pharma deals. The acquisition would boost Alexion's roster of rare disease drugs. (Reuters)
Healthcare performance software company Aetion has raised $36.4 million in Series B funding. New Enterprise Associates led the funding round, in the latest example of VCs backing healthcare tech. NEA general partner Mohamad Makhzoumi is joining the board of Aetion. (Wall Street Journal)
Roche has stopped enrollment in a combo study of Tecentriq and Cotellic after several deaths in a group of colon cancer patients. Treatment will continue for patients already enrolled in the study. (Endpoints)
Therapy video chat platform Talkspace has hired Neil Leibowitz as its chief medical officer. He was most recently senior medical director at UnitedHealth. Talkspace, which claims 1 million users, is reportedly considering an IPO. (CNBC)
Another study has found a link between traumatic brain injury and dementia later in life. The research on nearly 3 million Denmark residents' health records found severe or repeated brain injuries create the greatest danger for developing dementia (Associated Press).